These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 7879251

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacologic induction of weight loss to treat type 2 diabetes.
    Redmon JB, Raatz SK, Kwong CA, Swanson JE, Thomas W, Bantle JP.
    Diabetes Care; 1999 Jun; 22(6):896-903. PubMed ID: 10372238
    [Abstract] [Full Text] [Related]

  • 4. Smoking cessation in a patient being treated with fenfluramine plus phentermine for simple obesity.
    Rothman RB.
    J Clin Psychiatry; 1996 Feb; 57(2):92-3. PubMed ID: 8591979
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
    Roth JD, Trevaskis JL, Wilson J, Lei C, Athanacio J, Mack C, Kesty NC, Coffey T, Weyer C, Parkes DG.
    Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368
    [Abstract] [Full Text] [Related]

  • 8. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
    Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Cox C, Byrne L.
    Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The relationship between health-related quality of life and weight loss.
    Kolotkin RL, Crosby RD, Williams GR, Hartley GG, Nicol S.
    Obes Res; 2001 Sep; 9(9):564-71. PubMed ID: 11557837
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term drug treatment of obesity in a private practice setting.
    Atkinson RL, Blank RC, Schumacher D, Dhurandhar NV, Ritch DL.
    Obes Res; 1997 Nov; 5(6):578-86. PubMed ID: 9449143
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Appetite suppressants for obesity.
    Budenholzer B.
    J Fam Pract; 1997 Jan; 44(1):19-20. PubMed ID: 9010359
    [No Abstract] [Full Text] [Related]

  • 19. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.
    Weintraub M, Sundaresan PR, Schuster B, Moscucci M, Stein EC.
    Clin Pharmacol Ther; 1992 May; 51(5):602-7. PubMed ID: 1587074
    [Abstract] [Full Text] [Related]

  • 20. Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss.
    Katz DA, Maloney MJ, Sutkamp JC, McConville BJ.
    Int J Eat Disord; 1999 May; 25(4):469-74. PubMed ID: 10202659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.